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Abstract
Background: Compulsivity, the closely linked trait impulsivity and addictive behaviour are associated with several
neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder
(ASD), and obsessive compulsive disorder (OCD). All three disorders show impaired fronto-striatal functioning, which
may be related to altered glutamatergic signalling. Genetic factors are also thought to play an important role in the
aetiology of compulsivity-related disorders.
Methods: The COMPULS study is a multi-center study designed to investigate the relationship between the traits
compulsivity, impulsivity, and, to a lesser extent, addictive behaviour within and across the neurodevelopmental disorders
ADHD, ASD, and OCD. This will be done at the phenotypic, cognitive, neural, and genetic level. In total,
240 participants will take part in COMPULS across four different sites in Europe. Data collection will include
diagnostic interviews, behavioural questionnaires, cognitive measures, structural, functional and spectral
neuroimaging, and genome-wide genetic information.
Discussion: The COMPULS study will offer the unique opportunity to investigate several key aspects of
compulsivity across a large cohort of ADHD, ASD and OCD patients.
Keywords: Compulsivity, Fronto-striatal circuit, Glutamate, ADHD, ASD, OCD
Background
Compulsivity and impulsivity are cross-disorder traits
that are present across various neurodevelopmental
disorders, such as attention-deficit/hyperactivity disorder
(ADHD) autism spectrum disorder (ASD) and obsessive
compulsive disorder (OCD).
Compulsivity can be defined as the repetitive, irresistible
urge to perform certain behaviour, the experience of loss
of voluntary control over this intense urge, the diminished
ability to delay or inhibit thoughts and behaviours, and the
tendency to perform repetitive acts in a habitual or stereo-
typed manner [1, 2]. Compulsivity is a cross-disorder trait
observed in the phenotypically distinct neurodevelopmen-
tal disorders ASD and OCD. ASDs have a prevalence of
1.5% [3, 4] and are characterized by deficits in reciprocal
social interaction and communication and by restricted,
repetitive and stereotyped patterns of behaviour, interests
and activities [5]. OCD, on the other hand, is a relatively
common anxiety disorder, characterized by repetitive
thoughts, impulses, or images (obsessions), and repetitive
behaviours or mental acts (compulsions) that cause
marked distress [5]. OCD has its onset in late childhood
and is present in about 2.5% of the adult population [6].
Repetitive behaviours are among the core features of both
ASD and OCD, and comparison of symptom characteris-
tics has demonstrated more similarities than differences
[7]. In addition to symptom overlap, similar executive
function impairments related to inhibiting compulsive
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behaviours have been reported in first degree relatives of
people with ASD and OCD [8]. Compulsivity can be seen
as an overarching concept that includes both the failure to
resist an impulse, which links it to impulsivity, and
maladaptive habitual patterns of behaviours, which relates
to addictive behaviour.
Impulsivity is described as a predisposition toward
rapid unplanned reactions to internal or external stimuli
with diminished regard to the potentially negative conse-
quences of these reactions [2]. Impulsivity is one of the
core characteristics of ADHD. ADHD is characterized
by clinically significant levels of hyperactivity, impulsivity
and/or inattention and is affecting about 5% of all
school-age children world-wide [9, 10]. About 40% of
children with ADHD have comorbid ASD (e.g. [11–13]).
Further, prevalence of OCD in children with ADHD is
estimated at 8%, which is a 2-3 fold increase compared
to non-ADHD children [7, 14]. There are strong similar-
ities between the uncontrollable behaviour based on
impulsivity (seen in ADHD) and the excessive and
unwanted rituals related to compulsivity [15].
Addictive behaviour is characterized by both impul-
sivity and compulsivity [16]. One shows compulsive
drug-seeking, loss of control in limiting this intake,
and the emergence of a negative emotional state reflecting
a motivational withdrawal syndrome, when access to the
drug is prevented. Impulsivity often dominates early stages
of addiction, while compulsivity becomes important in later
stages. See Fig. 1 for the relation between compulsivity,
impulsivity and addictive behaviour in different disorders.
Separate but intercommunicating cortico-striatal circuits
seem to be involved in impulsivity and compulsivity [2, 17].
In the impulsive circuit, a striatal component (nucleus
accumbens) may drive impulsive behaviours, and a pre-
frontal component (anterior cingulate (ACC), ventromedial
prefrontal cortex) exerts inhibitory control. Similarly, com-
pulsive behaviour may be driven by a striatal component
(caudate, putamen), which is controlled by the orbitofrontal
cortex (OFC). Increased activity in the striatum and/or
decreased activity in the prefrontal cortex (PFC) may alter
the functioning of these cortico-striatal circuits and cause
impulsive or compulsive disorders, both characterized by
deficits in response inhibition. Although, in contrast to
impulsivity, compulsivity is considered a maladaptive per-
severation of behaviour that does not fall within the range
of normal behaviour [15], both patterns of behaviour often
co-occur [18, 19].
Compulsivity-related disorders differ in their age of
onset. ASD starts very early in life, ADHD in early child-
hood, and OCD has its onset in late childhood or early
adolescence. This variation in onset of impulsivity/com-
pulsivity may be related to variation in the maturation of
the fronto-striatal circuits and the role of glutamate
within these circuits. Recent theories suggest that striatal
brain regions underlying impulsive and compulsive
behaviours may show a nonlinear developmental pattern
with a peak inflection between 13 and 17 years of age
[20]. The prefrontal regions on the other hand, which
are important for top-down regulation of (striatum-
driven) impulsive and compulsive behaviour, show a
more linear pattern of maturation well into young
adulthood.
Glutamate is the major excitatory neurotransmitter in
the human brain and is critical to the understanding of
the top-down control of the prefrontal cortex over the
dorsal and ventral striatum [21]. The impulsivity- and
compulsivity-related fronto-striatal circuits are notable
for their relatively rich glutamatergic receptor density.
Glutamate modulates the neural activity and metabolism
of these circuits, as is reflected by the effects of
Fig. 1 Framework for understanding the relationships between cross-disorder traits impulsivity, compulsivity and addictive behaviours, between
discrete disorders, and between traits and disorders by adding a cognitive, neural, genetic and biomarker level of understanding. (ICD, impulse
control disorder)
Naaijen et al. BMC Psychiatry  (2016) 16:361 Page 2 of 10
glutamate on synapse induction and elimination as well
as synaptic transmission via ionotropic and metabotropic
glutamate receptors [22]. Indeed, glutamatergic projec-
tions from the prefrontal sub-regions to the striatum are
already known to play a key role in various compulsive
and impulsive behaviours including repetitive behaviours
such as stereotypy seen in ASD, impulsivity seen in
ADHD, and feelings of loss of control seen in OCD (for
a review, see [23]).
The study of genetics offers an opportunity to gather
additional evidence for the role of glutamate. Many
compulsivity- and impulsivity-related disorders are sub-
stantially heritable but genetically very complex, with
multiple genetic factors of varying penetrance implicated
[10, 24, 25]. A number of candidate genes have been
identified, suggesting glutamatergic pathways to operate
in ASD, ADHD, and OCD. For example, variation in
genes encoding the glutamate transporters SLC1A1,
SLC1A2, and SLC1A3 are strong candidate genes for
both ASD and OCD [26]. In addition, genes encoding
the NMDA receptors GRIN2A and GRIN2B have been
implicated in ASD ([27], and GRIN2B has also been
associated with ADHD [28] and OCD [29]. While glu-
tamate has an important role in the neurobiology of
compulsivity and impulsivity and the related disorders, it
is certainly not the only biological substrate involved.
For example, we have recently identified central insulin
signalling as an additional molecular cascade involved in
OCD [30] and neurite outgrowth as a neurodevelopmen-
tal process implicated in ADHD [31] and ASD [32].
Genetic variation in such genes is likely to alter their
regulation and/or function, leading to changes in the
encoded proteins and biological processes contributing
to proper cell function. Brain structure and brain func-
tion, also highly heritable, may mediate the effects of the
variation in genes and proteins on compulsive and
impulsive behaviours and related disorders [32, 33]. See
Fig. 2 for a representation of this relation between genes,
cell functioning, brain and behaviour.
Methods/Design
Aims of the study
COMPULS is a multicenter study as part of the over-
arching TACTICS study (http://www.tactics-project.eu)
investigating the relationship between the traits compul-
sivity, impulsivity, and - to a lesser extent - addictive
behaviour within and across the neurodevelopmental
disorders ASD, ADHD, and OCD. This will be the first
study to integrate these different traits and disorders
into one design. The primary objectives are to examine
whether these traits are related to structural and func-
tional connectivity of the fronto-striatal circuits and
whether these behavioural traits are predicted by or
related to abnormal glutamatergic concentrations in
these fronto-striatal circuits. Secondary objectives of
COMPULS are to explore the role of candidate genes or
candidate genetic pathways involved in compulsivity,
and related traits within these disorders.
These objectives will be investigated at the phenotypic,
cognitive, neural, and genetic level in a prospective
longitudinal design. This paper describes the design,
measures, and rationale of COMPULS.
Participants
Data collection occurs at four different sites across
Europe (Radboud university medical center and the
Donders Institute for Brain, Cognition and Behaviour,
Nijmegen, The Netherlands; Brain Centre Rudolf
Magnus, University Medical Centre Utrecht, Utrecht,
The Netherlands; King’s College London, London,
United Kingdom, and Central Institute of Mental
Health, Medical Faculty Mannheim, University of
Heidelberg Mannheim, Germany). We include 60
participants with ASD, 60 with OCD, 60 with ADHD,
and 60 healthy comparison participants in the age
range of 8 to 12 years. Every site includes 15 ASD,
OCD, and healthy comparison participants (adding up
to a total of 60 per group). The ADHD sample is
completely collected in Nijmegen. The total sample
size consists of 240 participants. Setting alpha at .05
(two-tailed) our sample size of N = 240 has 80% statis-
tical power to detect a beta (standardized regression
coefficient) of 0.21. This sample size allows for about
15 covariates/predictors in total. Thus our sample size
will provide us sufficient power to establish predictors of
small effect size. A group size of 60 participants per group
(OCD, ASD, ADHD, controls) further allows us to
examine the disease modifying effects in planned contrasts
in these regression models (dummy variables).
Inclusion criteria for all groups are age between 8
and 12 years old, IQ > 70, ability to speak and compre-
hend the native language of the country in which the
assessment takes place, and a signed informed consent
by parents or legal representatives. For the diagnosis
groups, a DSM-IV-TR or DSM-5 diagnosis of the
respective disorder has to be present. Exclusion cri-
teria for the ASD, OCD, and ADHD children are diag-
noses of the other disorders (comorbidity), e.g. an
OCD diagnosis in an ASD participant. Other exclusion
criteria include IQ < 70, major physical illness of the
vascular, endocrine, pulmonic or the gastrointestinal
system, all contra-indications for MR assessment, such
as the presence of metal objects in the body (i.e. pace-
maker, dental braces), and a history or presence of
neurological disorders. For the healthy comparison
participants, no first degree family members are
allowed to have any psychiatric disorder.
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Measures
Diagnosis
To determine the diagnoses several interviews will be
administered, depending on the symptoms of the partici-
pant. The autism diagnostic interview-revised (ADI-R
[34]) is a structured developmental interview adminis-
tered to the parent(s) to assess the symptoms of ASD
and make an ASD DSM-IV-TR diagnosis in the child.
For an ADHD diagnosis, the semi-structured Kiddie
Schedule for Affective Disorders and Schizophrenia (K-
SADS [35]) will be administered to the parent(s). The
Children’s Yale Brown Obsessive Compulsive Scale
(CYBOCS [36]) is used to interview the parent(s) and
child for the presence of obsessions and/or compulsions
and symptom severity, when OCD is present. This inter-
view will be performed in all participant groups when
screening questions confirm the presence of obsessions
or compulsions. In addition, all parents are interviewed
using the structured Diagnostic Interview Schedule for
Children (DISC [37]), the Development and Well-being
Assessment (DAWBA [38]) or the K-SADS to assess the
presence of possible comorbidities such as oppositional
defiant disorder, conduct disorder, and the presence of
tics/Tourette’s syndrome and anxiety disorders. The
diagnostic tools provide operational definitions of indi-
vidual symptoms as well as diagnosis-relevant questions,
such as onset of symptoms and impairment in several
areas of life.
Questionnaires
Questionnaires are used to assess (a) symptom severity of
possible comorbid disorders, such as ADHD (Conners’
Parent Rating Scale (CPRS R:L [39]) and ASDs (Children’s
Social Behavioural Questionnaire (CSBQ [40]), (b) Sub-
stance use disorders (SUDs; Alcohol Use Disorders Identifi-
cation Test (AUDIT [41]), drug abuse (Drug Abuse
Fig. 2 Simplified representation of relation between genes, cell functioning, brain functioning and behaviour. Many genes are involved in causing
disease symptoms, but reduced numbers of genes are involved in features associated with the disease symptoms, like brain functioning and cell
functioning (Adapted from [64])
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Screening Test (DAST [42]), and nicotine dependence
(Fagerstrøm Test for Nicotine Dependence (FTND [43]),
(c) lifetime alcohol-related problems (Michigan Alcohol
Screening Test (MAST [44]), (d) gambling problems
(South Oaks Gambling Screen (SOGS [45]), (e) repetitive
behaviour (Repetitive Behaviour Scale-Revised (RBS-R
[46]), (f) emotional and behavioural problems (Child
Behaviour Check List (CBCL [47]); Teacher report
form (TRF) [47]), and (g) physical development [48],
to determine the developmental stage at the time of
assessment. All questionnaires are completed by the
parent(s). A final set of measures is taken to deter-
mine patterns of use of prescribed medication (in
house self-report for medication use).
Cognitive assessment
All children complete an extensive protocol of cognitive
tasks measuring (a) intellectual functioning estimated
from the (i) vocabulary, (ii) block design, (iii) similarities,
and (iv) picture completion subtests of the WISC [49], (b)
motor inhibition, (c) cognitive flexibility, and (d) motor
speed. Except for the subtests of the WISC, all tests are
computerized. For cognitive flexibility, a timing task will
be administered [48, 49]. For measuring motor inhibition
and motor speed, we will use the set-shifting and baseline-
speed tasks of the Amsterdam Neuropsychological Tests
(ANT [50]).
MR measurements
Participating children complete a brain scan session in a
magnetic resonance imaging (MRI) scanner. At the four
different sites, comparable 3 Tesla MRI scanners are used
(Siemens Trio and Siemens Prisma, Siemens, Erlangen,
Germany; Philips 3 T Achieva, Philips Medical Systems,
Best, The Netherlands; General Electric MR750, GE
Medical Systems, Milwaukee, WI, USA) using a 32 channel
(Siemens) or 8 channel head coil (Philips, GE). A scanning
session includes an anatomical T1 scan, resting state func-
tional MRI (R-fMRI), Diffusion Tensor Imaging (DTI), and
two functional imaging tasks including a behavioural inhib-
ition (Stop) task [51] and a shortened monetary reward
anticipation task [52, 53]. COMPULS’ areas of interest are
the fronto-striatal circuits, important signalling regions that
are undergoing developmental changes in the age range of
8 to 12 years. As described in the introduction, differences
exist in the onset of compulsive disorders. In order to cap-
ture glutamatergic deficits across these disorders, an MR
spectroscopy session with two voxels of interest encom-
passing a part of these fronto-striatal circuits (left dorsal
striatum and ACC) is also included in the MRI session.
The structural T1 scanning sequences are based on the
ADNI GO protocols [54, 55] to be matched as closely as
possible across the different scanning sites. For R-fMRI we
use a multi-echo sequence to be able to separate BOLD
from non-BOLD signal more accurately [56], DTI acquisi-
tion is chosen to better resolve crossing fibers and task-
based fMRI acquisition is designed for optimal signal
stability and homogeneity over the different sites (see
Table 1 for an overview of the scan sequences). In order
to perform quality assessment of the MR scanning
sessions across four different sites, we will make use of
phantoms and so-called ‘travelling heads’. By using phan-
toms, we can assess subtle changes in scanner output over
time (due to scanner drifts, system upgrades, etc.), but we
feel that this is not sufficient to allow for calibration of
human brain data. In order to compare the quality of the
human brain scans across sites, the travelling heads are
thus used, i.e. three adult volunteers will travel to the four
participating sites at the start of COMPULS, at the end of
the data collection, and in-between, whenever scanner
upgrades are performed. This will allow us to assess inter-
scanner reliability and take into account differences
between scanners. These travelling head data-sets will
additionally be used to compare intra- and inter-site
variability with regard to the measurement of glutamate.
On-site MRS training will be provided before data-
collection to assure similarity in terms of voxel placement
across sites.
Genetic determinants
Participants will provide 40 ml blood for DNA-isolation
and assessment of biomarkers for which serum and plasma
fractions will be prepared. The venapuncture will be
performed by a trained practical nurse. If a participant
refuses venapuncture, saliva will be used for DNA-isolation
instead.
DNA, RNA, and plasma/serum fractions will be iso-
lated from blood/saliva using standard techniques and
stored at the department of Human Genetics of the
Radboud university medical center. MicroRNAs (miRNA)
will be extracted from total RNA isolated from blood
collected in PAX-gene tubes. The DNA will be subjected to
genome-wide genotyping, providing a basis for the compu-
tation of polygenic risk scores; such scores will be incorpo-
rated in analyses of disease risk, and might improve
phenotypic prediction [57]. The current study on itself will
have a small sample size and is of course insufficient to de-
tect genome-wide significant effects. However, by aggrega-
tion of multiple variants at the level of individual genes or
gene-sets through mass-univariate or multivariate methods,
power may be increased [58–60]. This will provide oppor-
tunities for candidate gene/pathway analyses, which of
course will require appropriate correction for multiple test-
ing. Lastly, by contributing to international collaborations
like the Psychiatric Genomics Consortium (PGC; [61] and
Enhancing Neuro Imaging Genetics through meta-analysis
(ENIGMA; [62])), our data may contribute to genome-wide
gene-finding studies will become more powerful.
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Protein and miRNA levels of blood-expressed candi-
date genes will be monitored. In the case of proteomics,
this will involve using multiplex immunoassay profiling
of serum. In addition, determination of glutamate,
serotonin, and insulin levels will be performed. This
work will be performed in the laboratory of Professor
Bahn in Cambridge.
Somatic and other measures
To obtain an estimate of possible abnormal growth or
other physiological abnormalities, we measure body
length, weight, waist circumference, and ask for the
presence of allergies or food restrictions.
Procedures
Assessment
After initial contact through information packages (in-
cluding general project information) sent by post, the
parents are phoned to check interest in participation. In
case of interest, a brief screening will be conducted to
control for possible exclusion criteria. If the child meets
the inclusion criteria, a questionnaire package will be
sent via regular post, also including informed consent/
assent forms and general information about the test-
location.
If feasible according to the child’s capability, one
testing day is organized covering all assessments. During
this day, parents will be assessed with the interview. If
screening questions are answered positively, screening
will be followed by the full supplementary module of the
specific disorder. When applicable, CYBOCS and/or the
ADI is administered. Cognitive tests with the child will
be administered in a fixed order and - due to the length
of the battery - split in two parts, part A and part B. The
order of administration of the two parts will be counter-
balanced across children. Before participating in the MR
session, children will be prepared for scanning using a
dummy scanner. In this dummy session, children are
presented with MR sounds, the button box needed for
task completion, and lying in a tight environment. In
addition, time to practice the MR tasks is provided
during this dummy session. Should a child (or his/her
parent) report anxiety to enter the MR scanner, the
session will be ended. The anxiety is monitored by using
a visual analogue scale (VAS), a scale from 1 to 10, on
which the child, parent, and researcher rate the anxiety
(1 means no anxiety and 10 means very high anxiety). If
the score is 8 or higher, the scan will not be performed.
After the MR assessment, the blood-sample will be taken
by trained professionals for biological analyses.
A monetary reward is granted and travel costs will be
reimbursed. Children who complete the MR session (or
at least the anatomical session) are provided with a
picture of their anatomical MR scan. Moreover, all
children receive an extra monetary reward, which they
can gain during the cognitive assessments (inside or out-
side the MR scanner), and a short report of their
performance on the IQ tests, if requested.
Table 1 Scan sequences
Sequence Site TR/TE/
TI (ms)
Flip
angle
Field of
view (mm)
Matrix RL/
AP/slices
Voxel-size
(mm)
Gap
(%)
Parallel
Imaging
b value Directions/b0’s Averages Water
suppressed/
unsuppressed
T1 Nijmegen
(Siemens)
2300*/2.98/900 9 256 212/256/176 1.0 * 1.0 * 1.2 NA 2 NA NA NA
Mannheim
(Siemens)
2300*/2.98/900 9 270 212/254/176 1.1 * 1.1 * 1.2 NA 2 NA NA NA
Utrecht
(Philips)
6.8*/3.10/823 9 270 204/252/170 1.1 * 1.1 * 1.2 NA 1.8 NA NA NA
London
(GE)
7.31*/3.02/400 11 270 256/256/196 1.1 * 1.1 * 1.2 NA 1.75 NA NA NA
MRS
PRESS
All 3000/30/- NA NA NA 20 * 20* 20 NA NA NA NA 96/16
R-FMRI# All 2300/12a–13b/- 80 240 240/240/33 3.8 * 3.8 * 3.8 11 2 – 2.5c NA NA NA
Functional
tasks
All 2070/35/- 74 192 192/192/36 3.0 * 3.0 * 3.0 13 2 NA NA NA
DTI All 12000/103/- 90 256 256/256/72 2.0 * 2.0 * 2.0 0 2 1500 60/2 NA
*As provided by the manufacturer. Philips and GE define a TR as the time an excitation pulse is given, while Siemens defines TR as the time between inversion
recovery pulses a volume
#Multi-echo resting state fMRI: TE2 is 31 ms for London and Utrecht, 29 for Mannheim and 28.41 for Nijmegen. TE3 is 48 for London, 49 for Utrecht, 46
for Mannheim and 44.82 for Nijmegen
aNijmegen, Mannheim
bUtrecht, London
cUtrecht
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Follow up
A second wave data collection procedure will be per-
formed after the first with an interval of at least 1 year.
The same measurements will be administered, except for
the ADI-R interview. These two time-points together can
give insights in development during an important phase in
life, when the transition from childhood and adolescence
takes place. The fronto-striatal circuit undergoes several
changes during development [63], which we can map
longitudinally with this study-design.
Staff training and supervision
The cognitive testing, diagnostic interview, and MRI
scanning are restricted to trained personnel. This
includes training in Good Clinical Practice (GCP). For
the diagnostic interview, staff members have to attend
interview sessions led by a trained interviewer. When
practicing interviews, one will be under supervision of a
clinician or trained professional. The ADI-R is an inter-
view that requires an official certificate and will only be
administered by those officially trained. For the diagnos-
tic interviews quality control meetings will be held to
discuss controversial cases and to maintain agreement.
To standardize cognitive testing and neuroimaging
sessions as much as possible, written standard operating
procedures (SOPs) were developed for administration of
cognitive tests and MR assessments. All researchers are
trained to administer the test battery using the SOPs
and under supervision before they can administer tests
on their own. The MRI training consists of practicing to
operate the scanner computer, learning security proce-
dures, and monitoring quality of the data (i.e. motion
artefacts, spike identification).
Data management and quality control
Every participant is coded with an anonymous identifier
number to separate personal data from scientific data.
Data acquisition will be documented in a case report
listing all data available for that person. Notes regarding
factors that may influence the data (analysis) are pro-
vided. Every note, questionnaire, informed consent form,
etc. will be kept together in a dossier. All digital data will
be stored on the device, on which it is administered (lap-
tops), and then securely uploaded to a central storage
server. This server backs-up to tape daily. Researchers at
the Radboud university medical center are also obligated
to archive raw data on at least two different archiving
disks.
All data, except for the MRI data, will be uploaded to
a central SQL (Structured Query Language) database.
This database meets the acquired safety regulations per
participating site, and only assigned researchers will have
access across the four sites. Data integrity will be
controlled by comparing uploaded data to descriptions
in the dossier. For MRI data, quality checks are also per-
formed. T1 anatomical scans are quality-rated on a 4-
point scale, MR spectra undergo visual inspection for
each participant, and various quantitative parameters are
calculated for the functional and diffusion imaging data,
such as spatial and temporal signal-to-noise-ratios and
realignment parameters.
Discussion
The COMPULS database will offer the unique oppor-
tunity to study several key aspects of compulsivity in a
large cohort of ASD, ADHD, and OCD patients. By
assessing neural and cognitive systems during the
critical period of transition from childhood to adoles-
cence across disorders, we can investigate stability and
changes of neural systems, which seem to be critical in
the development of compulsive behaviour. Integrating
data from cognitive, neural, and genetic markers linked to
compulsivity can largely increase our understanding of
neural mechanisms involved in compulsivity and related
disorders. Additionally, by using a dimensional approach
of compulsive and impulsive behaviour in several different
disorder groups, we can find differing and overlapping
deficits, which may explain the high comorbidity rates. At
the clinical level, this would provide means for identifying
children at risk for poor clinical outcome and provide a
basis for the development of better treatment strategies
that take into account this dimensional nature of neurode-
velopmental disorders. COMPULS will contribute its data
to meta- and mega-analyses in international initiatives like
the Psychiatric Genomics Consortium [61] and the
ENIGMA Consortium [62] and will collaborate with other
large international project with a focus on neurodevelop-
mental disorders (i.e. EU AIMS: http://www.eu-aims.eu/).
At the more technical and logistic level, the COMPULS
database will provide opportunities to thoroughly investi-
gate the effect of acquiring data at different centers on
outcome variables during analyses. It can examine which
types of data are most sensitive to the effect of multi-
centre collection, and can thus provide input for future
multi-center studies. It will form an international scientific
resource, which may be accessed by other researchers in
the field on request.
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